Kirsten L Bryant

17PUBLICATIONS
167CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 09, 2026
Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.

|Apr 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer.

|Nov 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Szu-Aun Long, Haley Todd, Grace Goodhart

|Sep 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|Jul 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp

Pageof 3

Frequent Collaborators

11 joint publications

Clint A Stalnecker

10 joint publications

Channing J Der

9 joint publications

Adrienne D Cox

6 joint publications

Kristina Drizyte-Miller